Evidence-based medicine proof and development trends of first-line treatment for advanced hepatocellular carcinoma

VernacularTitle:晚期肝细胞癌一线治疗新选择的循证医学证据及发展趋势
Author: Ming ZHAO ; Jiaming WU ; Ning LYU
From: Chinese Journal of Digestive Surgery 2021;20(2):191-196
CountryChina
Language:Chinese
Abstract: Tyrosine kinase inhibitors (TKIs) are used as the primary first-line treatment for advanced hepatocellular carcinoma, and the combination of immune checkpoint inhibitors (ICIs) and angiogenesis inhibitors have also been recommended as first-line treatment recently. For hepatocellular carcinoma patients with portal vein tumor thrombus, hepatic artery infusion chemotherapy (HAIC) is supported by progressively more evidence in improvement in the overall survival benefit. Based on relevant literatures and combined with clinical practices, the authors investigate the clinical application and development trends of TKIs, ICIs and HAIC in the first-line treatment for advanced hepatocellular carcinoma.